



# Antibacterial Effects of Margatoxin on Ciprofloxacin Resistant Clinical Isolates of *Acinetobacter baumannii*

Sahar Pourasgar<sup>1</sup>, Najmeh Ranji<sup>2\*</sup>, Leila Asadpour<sup>3</sup>, Mahdi Shahriarinoor<sup>4</sup>

<sup>1</sup> Department of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran.

<sup>2</sup> Department of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran

<sup>3</sup> Department of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran

<sup>4</sup> Department of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran

Received: 18 September 2023/ Revised: 10 October 2023/ Accepted: 17 October 2023

## Abstract

*Acinetobacter baumannii*, a gram-negative pathogen, is recognized as healthcare-associated opportunistic pathogens. In this study, the *in vitro* antibacterial properties of margatoxin (MgTX) were investigated against clinical isolates. The drug resistance profile of five antibiotics: piperacillin (100µg), imipenem (10µg), ceftazidime (30µg), amikacin (30µg), and ciprofloxacin (5µg) were evaluated with disc diffusion (Kirby-Bauer) method in 20 clinical isolates. Biofilm formation was assessed using the microtiter plate assay. Synergistic effects of MgTX in combination with ciprofloxacin was evaluated. Our results showed that the resistance to all antibiotics was  $\geq 90\%$ . All isolates were resistant to ciprofloxacin (128-1024 µg/mL). Additionally, all isolates had ability of biofilm formation (moderate to strong). Checkerboard method confirmed synergistic effect between MgTX and ciprofloxacin. indicated that a dose-dependent suppression of bacterial growth was achieved with the combined use of MgTX and ciprofloxacin. It seems that MgTX, with antibacterial properties, can use in therapeutic strategies in future against antibiotic resistant isolates.

**Key words:** *Acinetobacter baumannii*, ciprofloxacin, MgTX, Synergistic effect

---

\*Corresponding Author: E-mail: na.ranji@iaau.ac.ir



## Introduction

*Acinetobacter baumannii*, is a gram-negative, healthcare-associated opportunistic pathogens (Cain & Hamidian, 2023; Tacconelli et al., 2018). As one of the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *A. baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.*) *A. baumannii* poses a significant global threat to human health and presents a therapeutic challenge (Kyriakidis, Vasileiou, Pana, & Tragiannidis, 2021). Its high level of antibiotic resistance and biofilm formation contributes to a variety of infections, including those affecting the bloodstream, wounds, urinary tract, and lungs (Cain & Hamidian, 2023). The antibiotic resistance mechanisms employed by *A. baumannii* include alterations to target site (Martínez-Trejo et al., 2022), reduced outer membrane permeability (Chen, Liu, Zhang, Leung, & Xia, 2021), production of beta-lactamases, and overproduction of efflux pumps (Leão et al., 2023).

Scorpions, which have existed for over 400 million years, have developed an array of venom peptides during their evolution, making them a rich resource of antimicrobial peptides (AMPs) (Li, Yuan, Li, Deng, & Wang, 2020). Scorpion venom contains a variety of low-molecular-weight peptides, including amino acids, biogenic amines, enzymes, oligopeptides, nucleotides, lipids, mucoproteins, and other substances (Pashmforoosh & Baradaran, 2023). Previous studies have shown that AMPs interact specifically with bacterial cells membranes through electrostatic attraction, eradicating bacteria without inducing bacterial resistance (Li et al., 2020). Several AMPs have been identified from different scorpion species, including BmKn2 from *Buthus martensii* Karsch (Zeng, Wang, Zhu, Zhu, & Li, 2004), IsCTs from *Opisthacanthus madagascariensis* (Dai, Corzo, Naoki, Andriantsiferana, & Nakajima, 2002), Scorpine from *Pandinus imperator* (Casper, 1985), and MgTx from *Centruroides margaritatus* (Garcia-Calvo et al., 1993).

Margatoxin (MgTX), or Potassium channel toxin alpha-KTx 2.2, is a peptide derived from the venom of *Centruroides margaritatus* (de Oliveira, Soares, & Da Silva, 2023). MgTx is

a 39-amino-acid peptide toxin with a three-dimensional structure comprising an  $\alpha$ -helix and three antiparallel  $\beta$ -strands; stabilized by three disulfide bonds (Naseem et al., 2021). Scorpion venom peptides have been reports to possess various therapeutic properties, including antimicrobial, antibacterial, antifungal, antimycobacterial, cancer-biomarker, and cell penetrating capabilities (JAVED et al., 2022; Usmani, Agrawal, Sehgal, Patel, & Raghava, 2019). These peptides function primarily by forming pores in bacterial cell walls, leading to depolarization and subsequently antimicrobial effects (Mendoza-Tobar et al.). Given their high biological activity, AMPs are promising candidates for the treatment of antibiotics-resistant bacteria. This study examines the in vitro antibacterial properties of MgTx against isolates of *A. baumannii*. Additionally, we evaluated the drug resistance of the selected derivative and their synergistic effect with the antibiotic ciprofloxacin (CIP).

## Materials and methods

In this study, 150 clinical samples were collected from various hospitals and laboratories in the Tehran province. The reference strain, *Acinetobacter baumannii* ATCC 19606, was purchased from the Pasteur Institute of Iran.

The clinical isolates of *A. baumannii* were determined by biochemical and molecular testing. Molecular detection of *A. baumannii* isolates was performed with *bla-OXA-51* amplification. After DNA extraction with DNA pure Kit (Sinaclon, Iran), *bla-OXA-51* amplification was performed using PCR master mix kit (Sinaclon, Iran) and in Senso-Quest Labcycler thermocycler (Germany) according to manufacture program. The PCRs have been performed according to the following programs: an initial denaturation at 94 °C for 4 min, 30 cycles at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min, and a final extension step at 72 °C for 5 min. The oligonucleotide primers used for amplification and are described in Table 1. The presence or absence of *bla-OXA-51* gene was evaluated in 1.5% agarose gel electrophoresis.

## Antibiotic susceptibility profiles

Following the 2023 CLSI guidelines, the disc



**Table 1.** Sequence of primers used for PCR

Primer name	Primer sequence	Length of production	Reference
<i>blaOXA-51-F</i>	5'- TAATGCTTTGATCGGCCTTG - 3'	353 bp	Ghajavand, ) Esfahani, Havaei, Moghim, & Fazeli, (2015
<i>blaOXA-51-R</i>	5'- TGGATTGCACTTCATCTTGG - 3'		

diffusion method (Kirby-Bauer) was employed to identify the antibiotic resistance profiles in 20 clinical isolates of *A. baumannii* for five antibiotics: piperacillin (100µg), imipenem (10µg), ceftazidime (30µg), amikacin (30µg), and ciprofloxacin (5µg).

### Biofilm Formation assay

The microtiter plate assay (MTPA) was used to evaluate biofilm formation. *A. baumannii* ATCC 19606, a known biofilm producer, served as the positive control. All isolates and the reference strain were cultivated on Tryptic Soy Agar (TSA) medium (Merck, Germany) and incubated for 24hours at 37°C. Fresh colonies were inoculated in 10 mL of Tryptic Soy Broth (TSB) (Merck, Germany) and incubated for 15–18 hours at 37°C with shaking at 200 rpm. The optical density of each liquid culture was adjusted to 0.1 at 620 nm. The bacterial cultures were then diluted in TSB to prepare a suspension equivalent to 0.5 McFarland (0.5×10<sup>8</sup> CFU/mL). Each well of a 96-well polystyrene plate received 200 µL of bacterial the suspension. Plates were incubated for 72 hours at 37 °C.

Sterile broth was added to the negative control wells, and the control organism was similarly cultured and incubated. After incubation, the contents of each well were removed, and the wells were washed twice with phosphate buffer saline (PBS, pH 7) to eliminate free-floating bacteria. The wells were then fixed with 95% methanol for 10 minutes, stained with 1% crystal violet for 5 minutes, and excess stain was removed with sterile distilled water. After adding 100 µl of 33% glacial acetic acid to the wells, biofilm formation was measured at 570 nm using a Biotek ELx800 ELISA auto-reader (USA) (Mohsenzadeh et al., 2021).

Minimum Inhibitory Concentrations (MIC) of MgTX and CIP

The minimum inhibitory concentrations (MIC) of Margatoxin (MgTX) and ciprofloxacin (CIP) were determined using the microdilution method, following the Clinical and Laboratory Standards Institute (CLSI) protocol (MA, 2006). A 0.5 McFarland (0.5×10<sup>8</sup> CFU/mL) suspension of *A. baumannii* ATCC 19606 and six ciprofloxacin-resistant isolates was prepared in Muller-Hinton broth. Serial dilutions of MgTX and CIP, ranging from 1 to 1024 µg/mL, were prepared in tubes. After 24hours of incubation the MIC was determined.

### 2.4. Synergistic Effects of MgTX in combination with CIP

The synergistic effects of MgTX in combination with CIP against *A. baumannii* isolates were evaluated in vitro using the checkerboard dilution method. Eight different concentrations of MgTX and CIP were diluted in MHB. In each longitudinal column of wells, a constant concentration of MgTX was added, while each horizontal row of wells received a constant concentration of CIP. Each well contained a total volume of 200 µL, consisting of 50 µL MgTX, 50 µL CIP, and 100 µL of a bacterial suspension (final concentration of 5-7.5×10<sup>5</sup> CFU/mL). The fractional inhibitory concentrations index (FICI) was calculated


$$FICI = \frac{MIC (MgTX \text{ mixture})}{MIC (MgTX \text{ used alone})} + \frac{MIC (CIP \text{ mixture})}{MIC (CIP \text{ used alone})}$$

The results of the interaction were interpreted as follows: FICI≤0.5 shows synergy, 0.5<FICI≤0.75 shows partial synergy, 0.76<FICI≤1 shows additive interactions, 1<FICI≤4 shows lack of difference, FICI>4 shows antagonistic effects.


## Results

Antibiotic Susceptibility Profiles and Biofilm Formation of Isolates

A total of 150 clinical samples were collected, with men (65%) aged between 36 to 70 years rep-



**Figure 1.** A) Distribution of *A. baumannii* isolates. B) The gel electrophoresis image of PCR product of *blaOXA-51* (353 bp) DNA amplification in some isolates of *A. baumannii*.



**Figure 2.** A) Profile of *A. baumannii* isolates' Antibiotic susceptibility profile of *A. baumannii* isolates as determined by the disc diffusion method. B) MIC of CIP in isolates of *A. baumannii* in broth microdilution method. C) Biofilm formation ability of the isolates.



representing the majority of participants. Biochemical testing was employed to identify samples extracted from sputum, urine, burns, wounds, blood, and other sources (Figure 1A). Figure 1B demonstrated the presence of blaOXA-51 gene in the clinical isolates.

Figure 2A summarizes the antibiotic susceptibility profiles of the 20 *A. baumannii* isolates. Imipenem resistance was the highest among the isolates, with a rate of 100%. Ciprofloxacin and piperacillin resistance were also notably high, at 90%, followed by amikacin and ceftazidime with resistance rates of 90%. All clinical strains of *A. baumannii* tested positive for biofilm formation (moderate to strong). The semiquantitative results of the biofilm formation capabilities are presented in Figure 2C.

#### MIC of MgTX and CIP

The minimum inhibitory concentrations (MICs) of ciprofloxacin (CIP) for all isolates ranged from 128 and 1024 µg/mL (Figure 2B). MIC of MgTX was >1024 µg/mL for all the clinical isolates.

### Synergistic Effects of MgTX in combination with CIP

The synergistic effects of MgTX in combination with CIP were assessed using the Fraction-

al Inhibitory Concentration Index (FICI). The results of the checkerboard assay are presented in Table 1. As indicated, *A. baumannii* isolates demonstrated synergistic interactions between MgTX and CIP.

### Discussion

It is well established from various studies that multidrug-resistant bacteria have been growing exponentially worldwide (Pfalzgraff, Brandenburg, & Weindl, 2018). In this context, new therapeutic options must be developed to treat infections of ESKAPE pathogens (Pfalzgraff et al., 2018; Vojnits et al., 2024). One such pathogen is *Acinetobacter baumannii*, a leading sources of systemic dissemination and medical device colonization (Runci, Bonchi, Frangipani, Visaggio, & Visca, 2017). In this study, we evaluated antibacterial effects of MgTX in combination with ciprofloxacin. Our results showed that MgTX increased susceptibility of CIP in CIP resistant isolates. Numerous studies have revealed a notable rise in antimicrobial resistance to many agents globally (Lari, Ardebili, & Hashemi, 2018; Leite et al., 2016). Our results align with these studies, showing that *A. baumannii* exhibits high-level resistance to all first-line antibiotics, including anti-pseudomonal cephalosporins (ceftazidime),

**Table 1.** Interactive effects of MgTX in combination with CIP on *A. baumannii* isolates

Strains No.	MIC <sub>alone</sub> (µg ml <sup>-1</sup> )		MIC <sub>combined</sub> (µg ml <sup>-1</sup> )		FIC(µg/ml)
	CIP	MgTX	CIP	MgTX	
<b>ATCC</b>	1024	1024	16	32	0.0468*
<b>No.19</b>	512	1024	4	8	0.0156*
<b>No.26</b>	512	1024	8	8	0.0234*
<b>No.32</b>	512	1024	8	8	0.0234*
<b>No.33</b>	512	1024	4	8	0.0156*
<b>No.62</b>	512	1024	32	8	0.0703*
<b>No.70</b>	512	1024	4	8	0.0156*

\* FICI≤0.5 means synergy

\*\* 0.5 <FICI≤0.75 means partial synergy

\*\*\* 0.76 <FICI≤1 means additive



anti-pseudomonal carbapenems (imipenem), fluoroquinolones (ciprofloxacin) and aminoglycosides (amikacin). Consequently, it is critical to determine antibiotic susceptibility profiles and implement stringent infection control measures.

Given the strong antibiofilm and antibacterial potential of antimicrobial peptides (AMPs), they may serve as promising agents for treating *A. baumannii* infections (Pfalzgraff et al., 2018). Several studies have investigated the antibacterial properties of MgTX, with evidence suggesting that potassium channel inhibition disrupts bacterial membrane potential (Stautz et al., 2021). Ali MK et al. demonstrated that *A. baumannii* exposed to ciprofloxacin stress showed increased expression of the *kdpC* gene, which encodes a component of the KdpD/KdpE two-component system (TCS)-regulated potassium ion transporting ATPase complex (Ali et al., 2017). The potassium transport (Kdp) system is highly conserved in *A. baumannii* strains and plays a vital role in pathogenesis (Samir et al., 2016). Disruption of ion gradient can depolarize the bacterial cell membrane, which impairs critical biological processes, ultimately leading to bacterial cell death (Huang et al., 2020). MgTX may further interfere with ion homeostasis through its interaction with bacterial potassium channels, hindering physiological processes within bacterial cells (Stautz et al., 2021). In a recent study, a ciprofloxacin polypeptide-based polymer (PAC-NPs) demonstrated a broad-spectrum antibacterial effect against both Gram-positive and Gram-negative bacteria, with a minimum inhibitory concentration (MIC) ranging from 1.0 to 4.0 mg/mL and a sterilization rate exceeding 91% (Zhen et al., 2023). Our findings indicated that MgTX in combination with ciprofloxacin, exhibits dose-dependent suppression of bacterial growth, making it a promising candidate for antibacterial strategies against persistent *A. baumannii* infections.

## Conclusion

The growing drug resistance to conventional antibiotics underscores the urgent need to develop alternative antimicrobial agents. While few studies have explored the antibacterial properties of MgTX in recent decades, our investigation

findings suggest that MgTX has potential antibacterial effects in combination with antibiotics. It seems that MgTX can use as a complementary agent in the presence of antibiotics in drug resistant clinical isolates in future.

## Acknowledgements

The authors would like to extend their gratitude to Mohammad Zaefizadeh from Department of Biology, Islamic Azad University (Ardabil, Iran) for their support and assistance in this study.

## Conflict of interest

The authors declare no conflict of interest.

## Reference

- Ali, M. K., Li, X., Tang, Q., Liu, X., Chen, F., Xiao, J., . . . He, J. (2017). Regulation of inducible potassium transporter KdpFABC by the KdpD/KdpE two-component system in *Mycobacterium smegmatis*. *Frontiers in microbiology*, 8, 570.
- Cain, A. K., & Hamidian, M. (2023). Portrait of a killer: Uncovering resistance mechanisms and global spread of *Acinetobacter baumannii*. *PLoS Pathogens*, 19(8), e1011520.
- Casper, G. S. (1985). Prey capture and stinging behavior in the emperor scorpion, *Pandinus imperator* (Koch)(Scorpiones, Scorpionidae). *Journal of Arachnology*, 277-283.
- Chen, X., Liu, M., Zhang, P., Leung, S. S. Y., & Xia, J. (2021). Membrane-permeable antibacterial enzyme against multidrug-resistant *Acinetobacter baumannii*. *ACS Infectious Diseases*, 7(8), 2192-2204.
- Dai, L., Corzo, G., Naoki, H., Andriantsiferana, M., & Nakajima, T. (2002). Purification, structure-function analysis, and molecular characterization of novel linear peptides from scorpion *Opisthacanthus madagascariensis*. *Biochemical and biophysical research communications*, 293(5), 1514-1522.
- de Oliveira, A. N., Soares, A. M., & Da Silva, S. L. (2023). Why to Study Peptides from Venomous and Poisonous Animals? *International Journal of Peptide Research and Therapeutics*, 29(5), 76.
- Garcia-Calvo, M., Leonard, R., Novick, J., Stevens, S., Schmalhofer, W., Kaczorowski, G., & Garcia, M. (1993). Purification, characterization, and biosynthesis of margatoxin, a component of *Centruroides margaritatus* venom that selectively inhibits voltage-dependent potassium channels. *Journal of Biological Chemistry*, 268(25), 18866-18874.
- Ghajavand, H., Esfahani, B. N., Havaei, S. A., Moghim, S., & Fazeli, H. (2015). Molecular identification of *Acinetobacter baumannii* isolated from



intensive care units and their antimicrobial resistance patterns. *Advanced biomedical research*, 4(1), 110.

Huang, M., Zhuang, H., Zhao, J., Wang, J., Yan, W., & Zhang, J. (2020). Differences in cellular damage induced by dielectric barrier discharge plasma between *Salmonella typhimurium* and *Staphylococcus aureus*. *Bioelectrochemistry*, 132, 107445.

JAVED, M., HUSSAIN, S., KHAN, M. A., TAJAMMAL, A., FATIMA, H., AMJAD, M., . . . YAQOOB, M. (2022). Potential of Scorpion Venom for the treatment of various diseases. *International Journal of Chemistry Research*, 1-9.

Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Triagiannidis, A. (2021). *Acinetobacter baumannii* antibiotic resistance mechanisms. *Pathogens*, 10(3), 373.

Lari, A. R., Ardebili, A., & Hashemi, A. (2018). AdeR-AdeS mutations & overexpression of the AdeABC efflux system in ciprofloxacin-resistant *Acinetobacter baumannii* clinical isolates. *The Indian journal of medical research*, 147(4), 413.

Leão, P. V. S., Ferreira, A. L. d. S., Oliveira, F. A. d. A., Mesquita, A. B. d. S., Lima-Net, J. d. S., Gutierrez, S. J. C., . . . Barreto, H. M. (2023). Riparin-B as a Potential Inhibitor of AdeABC Efflux System from *Acinetobacter baumannii*. *Evidence-Based Complementary and Alternative Medicine*, 2023.

Leite, G. C., Oliveira, M. S., Perdigao-Neto, L. V., Rocha, C. K. D., Guimaraes, T., Rizek, C., . . . Costa, S. F. (2016). Antimicrobial combinations against pan-resistant *Acinetobacter baumannii* isolates with different resistance mechanisms. *PloS one*, 11(3), e0151270.

Li, Z., Yuan, Y., Li, S., Deng, B., & Wang, Y. (2020). Antibacterial activity of a scorpion-derived peptide and its derivatives in vitro and in vivo. *Toxicology*, 186, 35-41.

MA, W. (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. *Clsi (Necls)*, 26, M7-A7.

Martínez-Trejo, A., Ruiz-Ruiz, J. M., Gonzalez-Avila, L. U., Saldaña-Padilla, A., Hernández-Cortez, C., Loyola-Cruz, M. A., . . . Castro-Escarpulli, G. (2022). Evasion of Antimicrobial Activity in *Acinetobacter baumannii* by Target Site Modifications: An Effective Resistance Mechanism. *International Journal of Molecular Sciences*, 23(12), 6582.

Mendoza-Tobar, L. L., Clement, H., Arenas, I., Guerrero-Vargas, J. A., Hernandez-Orihuela, L., Sepulveda-Arias, J. C., & Corzo, G. Antimicrobial, Toxicological, and Antigenic Characteristics of Three Scorpion Venoms from Colombia: *Centruroides margaritatus*, *Tityus pachyurus* and *Tityus* N. Sp. Aff.

*Metuendus*. Sp. Aff. *Metuendus*.

Mohsenzadeh, A., Fazel, A., Bavari, S., Borji, S., Pourasghar, S., Azimi, T., & Sabati, H. (2021). Detecting of biofilm formation in the clinical isolates of *Pseudomonas aeruginosa* and *Escherichia coli*: an evaluation of different screening methods. *Journal of Current Biomedical Reports*, 2(2), 56-61.

Naseem, M. U., Tajti, G., Gaspar, A., Szanto, T. G., Borrego, J., & Panyi, G. (2021). Optimization of *Pichia pastoris* expression system for high-level production of margatoxin. *Frontiers in Pharmacology*, 12, 733610.

Pashmforoosh, N., & Baradaran, M. (2023). Peptides with Diverse Functions from Scorpion Venom: A Great Opportunity for the Treatment of a Wide Variety of Diseases. *Iranian biomedical journal*, 27(2-3), 84.

Pfalzgraff, A., Brandenburg, K., & Weindl, G. (2018). Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. *Frontiers in pharmacology*, 9, 281.

Runci, F., Bonchi, C., Frangipani, E., Visaggio, D., & Visca, P. (2017). *Acinetobacter baumannii* biofilm formation in human serum and disruption by gallium. *Antimicrobial agents and chemotherapy*, 61(1), 10.1128/aac.01563-01516.

Samir, R., Hussein, S. H., Elhosseiny, N. M., Khattab, M. S., Shawky, A. E., & Attia, A. S. (2016). Adaptation to potassium-limitation is essential for *Acinetobacter baumannii* pneumonia pathogenesis. *The Journal of Infectious Diseases*, 214(12), 2006-2013.

Stautz, J., Hellmich, Y., Fuss, M. F., Silberberg, J. M., Devlin, J. R., Stockbridge, R. B., & Hänelt, I. (2021). Molecular mechanisms for bacterial potassium homeostasis. *Journal of molecular biology*, 433(16), 166968.

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., . . . Carmeli, Y. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet infectious diseases*, 18(3), 318-327.

Usmani, S. S., Agrawal, P., Sehgal, M., Patel, P. K., & Raghava, G. P. (2019). ImmunoSPdb: an archive of immunosuppressive peptides. *Database*, 2019, baz012.

Vojnits, K., Mohseni, M., Parvinzadeh Gashti, M., Nadaraja, A. V., Karimianghadim, R., Crowther, B., . . . Pakpour, S. (2024). Advancing Antimicrobial Textiles: A Comprehensive Study on Combating ES-KAPE Pathogens and Ensuring User Safety. *Materi-*



als, 17(2), 383.

Zeng, X.-C., Wang, S.-X., Zhu, Y., Zhu, S.-Y., & Li, W.-X. (2004). Identification and functional characterization of novel scorpion venom peptides with no disulfide bridge from *Buthus martensii* Karsch. *Peptides*, 25(2), 143-150.

Zhen, J.-B., Yi, J.-J., Liu, B.-X., Liu, Y.-J., Bu, X.-Y., Wu, X.-J., & Tang, D. (2023). Ciprofloxacin peptide-based nanoparticles confer antimicrobial efficacy against multidrug-resistant bacteria. *New Journal of Chemistry*, 47(48), 22377-22387.